Ambrisentan vs F230
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: Endothelin A receptor · full Pulmonary Arterial Hypertension pipeline
Ambrisentan · Letairis
Marketed by Gilead Sciences and partners
NCT00423202 · Phase 3 · completed
The trial's own title and endpoint description confirm a randomized, double-blind, placebo-controlled design with a validated functional endpoint for pulmonary hypertension. Both doses significantly improved six-minute walk distance over placebo (+32 m at 2.5 mg, p=0.022; +59 m at 5 mg, p<0.001).
Next expected readout: February 2028 · NCT06987097 (registry estimate)
Reported efficacy
Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV (From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)): Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction (met)
Result source: NCT01178073
F230
Developed by Gyre Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
F230: no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ambrisentan
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 7 more results
show 1 more result
show 2 more results
show 19 more results
show 12 more results
show 1 more result
+ 46 further endpoints in the CSV export.
Available safety results
Ambrisentan
| Dropout rate | 28.9%Ambrisentan Monotherapy NCT01178073 · Phase 3 · monotherapy show 15 more results20.5%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · combination 7.5% NCT01808313 · Phase 3 26.7% NCT01338636 · Phase 4 · registry result, not featured evidence 4% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01330108 · Phase 4 · registry result, not featured evidence 24.2% NCT00617305 · Phase 4 · registry result, not featured evidence 30.9%10 mg NCT00578786 · Phase 3 · registry result, not featured evidence 34.7%5 mg NCT00578786 · Phase 3 · registry result, not featured evidence 40.6%2.5 mg NCT00578786 · Phase 3 · registry result, not featured evidence 10.5% NCT02290613 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT00424021 · Phase 2 · registry result, not featured evidence 6.3%5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 15.8%2.5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 6.3%1 mg NCT00424021 · Phase 2 · registry result, not featured evidence 19.4% NCT00423592 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 17.8%Ambrisentan Monotherapy NCT01178073 · Phase 3 · monotherapy show 15 more results11.3%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · combination 3.8% NCT01808313 · Phase 3 — NCT01338636 · Phase 4 · registry result, not featured evidence — NCT01042158 · Phase 4 · registry result, not featured evidence · combination — NCT01330108 · Phase 4 · registry result, not featured evidence 12.1% NCT00617305 · Phase 4 · registry result, not featured evidence 17.5%10 mg NCT00578786 · Phase 3 · registry result, not featured evidence 19.5%5 mg NCT00578786 · Phase 3 · registry result, not featured evidence 28.1%2.5 mg NCT00578786 · Phase 3 · registry result, not featured evidence — NCT02290613 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT00424021 · Phase 2 · registry result, not featured evidence 6.3%5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 6.3%1 mg NCT00424021 · Phase 2 · registry result, not featured evidence 19.4% NCT00423592 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 41.4%Ambrisentan Monotherapy NCT01178073 · Phase 3 · monotherapy show 15 more results41.1%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · combination 8.2% NCT01808313 · Phase 3 0% NCT01338636 · Phase 4 · registry result, not featured evidence 12.5% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 0% NCT01330108 · Phase 4 · registry result, not featured evidence 30.3% NCT00617305 · Phase 4 · registry result, not featured evidence 53.1%10 mg NCT00578786 · Phase 3 · registry result, not featured evidence 52.1%5 mg NCT00578786 · Phase 3 · registry result, not featured evidence 60.5%2.5 mg NCT00578786 · Phase 3 · registry result, not featured evidence 5.3% NCT02290613 · Phase 2 · registry result, not featured evidence 69.2%10 mg NCT00424021 · Phase 2 · registry result, not featured evidence 63.2%5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 28.6%2.5 mg NCT00424021 · Phase 2 · registry result, not featured evidence 0%1 mg NCT00424021 · Phase 2 · registry result, not featured evidence 47.2% NCT00423592 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 14 more resultsworsening dyspnea on exertion 26.7% nasal congestion 23.3% peripheral edema 23.3% NCT01338636 · Phase 4 · registry result, not featured evidence edema 31.3% lower extremity edema 6.3% rash 3.1% NCT01330108 · Phase 4 · registry result, not featured evidence nasal congestion 30.3% upper respiratory tract infection 24.2% headache 21.2% NCT00617305 · Phase 4 · registry result, not featured evidence 10 mg oedema peripheal 52.1% headache 31.4% upper respiratory tract infection 25.8% NCT00578786 · Phase 3 · registry result, not featured evidence 5 mg oedema peripheal 36.3% headache 23.3% cough 17.8% NCT00578786 · Phase 3 · registry result, not featured evidence 2.5 mg oedema peripheal 30.2% pulmonary hypertension 16.3% anaemia 14% NCT00578786 · Phase 3 · registry result, not featured evidence edema 42.1% (placebo 21.1%) headache 31.6% (placebo 31.6%) diarrhea 21.1% (placebo 10.5%) NCT02290613 · Phase 2 · registry result, not featured evidence 10 mg oedema peripheral 57.7% upper respiratory tract infection nos 53.8% nausea 38.5% NCT00424021 · Phase 2 · registry result, not featured evidence 5 mg oedema peripheral 63.2% cough 47.4% dyspnoea exacerbated 47.4% NCT00424021 · Phase 2 · registry result, not featured evidence 2.5 mg bronchitis nos 57.1% chest pain 57.1% upper respiratory tract infection nos 57.1% NCT00424021 · Phase 2 · registry result, not featured evidence 1 mg alanine aminotransferase increased 100% aspartate aminotransferase increased 100% angina pectoris 50% NCT00424021 · Phase 2 · registry result, not featured evidence oedema peripheral 52.8% headache 36.1% dyspnoea exacerbated 33.3% NCT00423592 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ambrisentan's landscape · F230's landscape